As PSA tests fall, metastatic prostate cancer rises

EFFORTS to rein in PSA testing have coincided with a marked rise in metastatic prostate cancer in the US, new data shows.

There's no equivalent data in Australia, but urologists are now concerned that a similar pattern could emerge closer to home.

PSA testing in the US declined from 2008, after the Preventive Services Task Force issued a caution about the risks of false positives and resultant overtreatment.

To clarify the impact of screening changes on prostate cancer, researchers analysed the national US cancer database and found 768,000 men who had been diagnosed between 2004 and 2013.